Drug Trial Radar · NCT04772365
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 1, 2021
Primary completion
Dec 10, 2021
Study completion Dec 10, 2021
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, randomized, double-blind, placebo-controlled, single and multiple dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy subjects
Conditions
- Asthma
Interventions
SHR-1819Drug
SHR-1819 will be subcutaneously administered with different dose levels;
PlaceboDrug
Placebo will be subcutaneously administered with different dose levels;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Start of Treatment to end of study(about 13 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Xiangya Hospital of Central South University
Changsha, Changsha, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.